NCT04028245 - A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 15, 2019

Primary Completion Date

March 14, 2025

Study Completion Date

March 31, 2026

Conditions

Carcinoma, Renal Cell

Interventions

DRUG

Spartalizumab

Spartalizumab at 400 mg weeks x 2 doses prior to radical nephrectomy Infusion

DRUG

Canakinumab

Canakinumab 300 mg IV Q4 weeks x 2 doses prior to radical nephrectomy Infusion

Trial Locations (1)

Columbia University Irving Medical Center, New York